FDA updates MQSA guidance for DBT

The U.S. Food and Drug Administration (FDA) has updated its guidance on Mammography Quality Standards Act (MQSA) training requirements for digital breast tomosynthesis (DBT).

The updated version states that manufacturer-specific training is no longer required; personnel need only obtain training on one DBT system or obtain general DBT training to meet the modality training requirement, the FDA said. However, because some systems have unique features, users are encouraged to receive additional training as needed.